Diabetic Foot Ulcers - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 109

Diabetic Foot Ulcers - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Diabetic Foot Ulcers - Pipeline Review, H2 2011', provides an overview of the Diabetic Foot Ulcers therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers. 'Diabetic Foot Ulcers - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Foot Ulcers.
- A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Foot Ulcers pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Diabetic Foot Ulcers therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Foot Ulcers Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Foot Ulcers
Diabetic Foot Ulcers Therapeutics under Development by Companies
Diabetic Foot Ulcers Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Diabetic Foot Ulcers Therapeutics - Products under Development by Companies
Diabetic Foot Ulcers Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diabetic Foot Ulcers Therapeutics Development
Cardium Therapeutics, Inc.
Sanofi-Aventis
Biotec Pharmacon ASA
CardioVascular BioTherapeutics, Inc.
Reliance Life Sciences Pvt. Ltd.
Nanotherapeutics, Inc.
Pfizer Inc.
RegeneRx Biopharmaceuticals, Inc.
Ahn-Gook Pharmaceutical Co., Ltd.
Pluristem Therapeutics Inc.
Microbio Co., Ltd.
CytoTools AG
Healthpoint, Ltd.
CoMentis, Inc.
Glycotex, Inc.
Phage Biotechnology Corporation
NovaLead Pharma Pvt. Ltd.
BRIDGE BIORESEARCH PLC
USV Limited.
CoDa Therapeutics, Inc.
Innocoll, Inc.
Adocia
Agennix AG
Praxis Pharmaceuticals Inc.
Diabetic Foot Ulcers - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CVBT-141B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoDOX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Excellarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chrysalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mebo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CollaRx Gentamicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Talactoferrin Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyzact - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermaPro CI 05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1 141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATG002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Soluble Beta Glucan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO 03 03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Galnobax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fragmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DCB-WH1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG SPT201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gentamicin Collagen Sponge + Levaquin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cogenzia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DSC127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tissue Repair Cells (TRC) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angipars - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nitric Oxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trafermin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nautiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Stem Cell Transfer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urokinase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angipars - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vasculotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF + Autologous Peripheral Blood Mononuclear Cell Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-DFU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Platelet Derived Growth Factor Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBR-012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NU200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Circulating Fibrocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PX070101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ReliDermDT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neurotensin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Foot Ulcers Therapeutics – Drug Profile Updates
Diabetic Foot Ulcers Therapeutics - Discontinued Products
Diabetic Foot Ulcers - Featured News
Sep 01, 2011: Kuros Completes Patient Recruitment In Phase IIb Clinical Trial With KUR-211 For Diabetic Foot Ulcers
Jun 15, 2011: Adocia SAS announces the communication of its clinical results at three major conferences
May 25, 2011: Derma Sciences Reports Continued Healing At 24 Weeks In Patients With Diabetic Foot Ulcers Treated With DSC127 In Phase II Trial
Mar 15, 2011: Pluristem Therapeutics And NYU Medical Center Partner To Study Use Of PLX Cells In Treatment Of Diabetic Foot Ulcers
Feb 03, 2011: Derma Sciences Reports Positive Top-Line Results From DSC127 Phase II Trial In Patients With Diabetic Foot Ulcers
Sep 14, 2010: Derma Sciences To Complete Enrollment In DSC127 Phase II Wound Healing Trial
Jul 13, 2010: Innocoll Submits SPA For Cogenzia Phase III Clinical Trials For Adjuvant Treatment Of Diabetic Foot Ulcers
Jun 30, 2010: DermaTools Biotech Has Received The Green Light From The BfArM For Phase II Clinical Trials Of Patients Suffering From Diabetic Foot Ulcer In Germany
Apr 26, 2010: Start of Phase III Of DermaPro In India
Jan 26, 2010: Green Light From India For Dermapro – Start Of Phase III After Protocol Optimization
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Commercial And Military Flight Simulation - Global Strategic Business Report
• International Military and Government Helicopter Survey
• Global Mobile Defense Rescue & Security Robots – Sensors & Payloads: Markets & Technologies Outlook – 2012-2017
• Aerospace and Defense Industry - Global Outlook